Oruka Therapeutics, Inc.
80.15USD
-1.0000 (-1.23%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ORKA.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -50 | -36 | -34 | -34 | -28 | -25 | -29 | -21 |
| Net Income | -41 | -32 | -30 | -30 | -25 | -21 | -29 | -22 |
| EPS (Diluted) | — | — | — | — | -$0.46 | -$0.40 | -$1.46 | -$6.96 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)